Allograft inflammatory factor 1 (AIF1) (AIF1)

Allograft inflammatory factor 1 (AIF1), frequently referred to as Iba1, is a calcium-binding protein that is highly conserved and specifically expressed in macrophages and microglia (UniProt P55008). It functions as a key regulator of the actin cytoskeleton, facilitating membrane ruffling, phagocytosis, and cell migration during the inflammatory response (PubMed: 28611155). In clinical and research settings, AIF1 is most recognized as a definitive biomarker for microglial activation in the brain, with its expression levels correlating with the progression of neurodegenerative diseases like Alzheimer's and Parkinson's (PubMed: 30250272). Beyond its role as a marker, AIF1 is considered a potential therapeutic target; silencing AIF1 mRNA using RNA interference has been shown to reduce the severity of inflammatory conditions such as rheumatoid arthritis and transplant rejection in animal models (PubMed: 12734315). Targeting AIF1 mRNA aims to modulate the activation state of myeloid cells, potentially offering a way to dampen chronic inflammation without broad-spectrum immunosuppression (PubMed: 11044501). However, therapeutic development remains largely in the preclinical stage, focusing on the use of antisense technologies to control its expression (PubMed: 16330530).

Other names

Iba1Ionized calcium-binding adapter molecule 1Protein G1AIF-1IRT-1Daintain

Antisense or siRNA-mediated degradation of AIF1 mRNA to inhibit the synthesis of the AIF1 protein, leading to reduced actin polymerization and suppressed myeloid cell activation (PubMed: 12734315).